Pfizer and Merck Pursue Divergent Strategies as Pipeline Pressures Mount
核心洞察
Pfizer delivers strong Q4 2025 results with $0.66 adjusted EPS beat while maintaining 6.58% dividend yield backed by robust non-COVID portfolio growth including 136% surge in Abrysvo revenue.
Merck (搜索) reports Q1 2026 earnings dominated by $9 billion Cidara acquisition charge as company accelerates post-KEYTRUDA portfolio development with KEYTRUDA generating $8.03 billion in quarterly revenue.
Both companies face critical patent cliff challenges with Pfizer's $7 billion Metsera obesity (搜索) acquisition targeting GLP-1 (搜索) competition while Merck (搜索) confronts KEYTRUDA biosimilar threats representing 50% of pharma revenue.
Pfizer and Merck (搜索) have delivered contrasting earnings reports that highlight their divergent strategic approaches as both pharmaceutical giants navigate significant pipeline pressures and patent cliff challenges heading into 2026.
Pfizer Delivers Strong Q4 Performance Amid Strategic Transformation
Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat, demonstrating resilience as COVID revenue continues to fade. The company now offers a 6.58% dividend yield, distributing $9.8 billion in 2025 dividends at $1.72 per share. This payout sits on a $3.22 adjusted EPS base, providing comfortable coverage with a 53% payout ratio.
Non-COVID growth metrics revealed the strength of Pfizer's diversified portfolio. Abrysvo revenue jumped 136%, Eliquis added 10% growth, and oncology biosimilars surged 77%. These gains underscore the company's successful transition away from pandemic-driven revenues.
CEO Albert Bourla emphasized the company's strategic focus, telling investors that "2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts." Management is targeting $7.2 billion in net cost savings by 2027 while keeping buybacks off the table, signaling that dividend sustainability remains the priority.
Merck Accelerates Acquisition Strategy Despite Revenue Headwinds
Merck (搜索)'s Q1 2026 report was dominated by a $9 billion Cidara acquisition charge as the company aggressively builds its post-KEYTRUDA portfolio. Despite this charge, underlying business performance showed strength with KEYTRUDA delivering $8.03 billion in quarterly revenue, up 12% year-over-year.
WINREVAIR demonstrated exceptional growth, rocketing 88% to $525 million in quarterly revenue, while Animal Health added a steady 13% growth. The company recently increased its quarterly dividend from $0.81 to $0.85, reflecting confidence in cash flow generation despite heavy acquisition spending.
However, challenges emerged in key markets. GARDASIL revenue in China fell 47%, and interest expense climbed to $479 million as the company finances its acquisition spree. The Cidara deal has closed, while the Terns (搜索) acquisition remains pending at approximately $5.8 billion, and Verona Pharma already contributed $131 million in Q1 revenue.
Critical Patent Defense Challenges Ahead
Both companies face significant patent cliff pressures that will define their near-term trajectories. For Pfizer, the $7 billion Metsera acquisition represents a bold push into the obesity (搜索) market, targeting ultra-long-acting GLP-1 (搜索) candidates that must compete credibly with established players Novo Nordisk and Eli Lilly. The company faces a manageable $1.5 billion loss-of-exclusivity headwind in 2026, but obesity execution will be the critical swing factor.
Merck (搜索) confronts a more immediate challenge with the KEYTRUDA biosimilar clock, given the drug represents roughly 50% of pharmaceutical revenue. The company's aggressive acquisition strategy reflects urgency in building alternative revenue streams before patent expiration. WINREVAIR and the animal health franchise must continue compounding growth to offset eventual KEYTRUDA declines.
Divergent Investment Profiles Emerge
The two companies now present distinctly different investment profiles. Pfizer trades at a forward P/E of 9 while offering its 6.58% yield, appealing to income-focused investors seeking immediate returns. The company's strategic focus on dividend sustainability over share buybacks provides clarity on capital allocation priorities.
Merck (搜索) commands a premium valuation at 23 times forward earnings while offering a 2.74% yield on its $3.28 annual dividend. The company's 61.04% one-year stock return reflects investor confidence in its growth trajectory, though this comes with higher execution risk as management navigates multiple large acquisitions while defending against patent cliffs.